Corbus Pharmaceuticals Holdings, Inc.
CRBP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CRBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRBP
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage oncology and obesity company developing a diversified portfolio of therapies, including CRB-701 and CRB-913, with no approved products and a history of operating losses.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$211.0M
Cash Runway
11.6 moLead Asset
CRB-601 (Phase 3)
Next Catalyst
Phase3_Topline · Mar 1, 2029Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 4 clinical trials · 1 catalyst for Corbus Pharmaceuticals Holdings, Inc..
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage oncology and obesity company developing a diversified portfolio of therapies, including CRB-701 and CRB-913, with no approved products and a history of operating losses.
- Corbus is a clinical-stage company focused on oncology and obesity, with a diversified portfolio of product candidates [sec_mda · as of 2026-03-09].
- As of June 30, 2026, the company reported cash and equivalents of $23.8M, net income of -$35.0M, and shareholders' equity of $147.5M [sec].
- Research and development expenses for the three months ended June 30, 2026 totaled $31.2 million, driven by increased costs for CRB-701 and CRB-913 [sec_mda · as of 2026-08-06].
- The company has never been profitable and had an accumulated deficit of $555.4 million as of December 31, 2025 [sec_mda · as of 2026-03-09].
What works
- Corbus has a diversified portfolio targeting oncology and obesity, with multiple product candidates in clinical development [sec_mda · as of 2026-03-09].
- The company raised net proceeds of approximately $9.1 million from stock sales in the first half of 2026, providing additional funding for operations [sec_mda · as of 2026-08-06].
- Cash, cash equivalents, and investments of approximately $117.9 million at June 30, 2026 are expected to fund operations for at least twelve months [sec_mda · as of 2026-08-06].
What to weigh
- Corbus has never been profitable and reported a net loss of $78.5 million for the year ended December 31, 2025 [sec_mda · as of 2026-03-09].
- The company will need to raise significant additional capital to continue funding clinical trials and operations beyond the current cash runway [sec_mda · as of 2026-08-06].
- Research and development expenses increased significantly, with total program-specific costs rising by $15.7 million for the three months ended June 30, 2026 compared to the prior year [sec_mda · as of 2026-08-06].
- The company does not expect to generate revenue from product sales unless and until it obtains regulatory approval, which is subject to significant uncertainty and expected to take several years [sec_mda · as of 2026-03-09].
From the filings
Quoted directly from source documents.
Corbus is a clinical-stage oncology and obesity company.
“We are a clinical stage company focused on promising new therapies in oncology and obesity”
SEC MD&A · March 9, 2026
The company has never been profitable and has a large accumulated deficit.
“We have never been profitable and at December 31, 2025, we had an accumulated deficit of $555.4 million.”
SEC MD&A · March 9, 2026
Cash runway is expected to last at least twelve months from June 30, 2026.
“we expect our cash, cash equivalents, and investments of approximately $117.9 million at June 30, 2026 will be sufficient to meet our operating and capital requirements through at least twelve months from the issuance of this Quarterly Report on Form 10-Q.”
SEC MD&A · August 6, 2026
R&D expenses increased significantly in Q2 2026.
“development expenses for the three months ended June 30, 2026 totaled $31.2 million, an increase of $16.0 million from $15.2 million recorded for the three months ended June 30, 2025.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2029-03-01 · Phase3_Topline — Phase 3 Topline: A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator' — Topline results from the Phase 3 trial of CRB-701 will be a key readout for the program's efficacy and safety profile.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Corbus has no approved products and does not expect revenue from product sales for several years, if ever [sec_mda · as of 2026-03-09].
- Need for additional capital — The company will need to raise significant additional capital to continue funding clinical trials and operations [sec_mda · as of 2026-08-06].
- History of operating losses — Corbus has never been profitable, with a net loss of $78.5M in 2025 and an accumulated deficit of $555.4M [sec_mda · as of 2026-03-09].
- Clinical development uncertainty — The success of product candidates like CRB-701 and CRB-913 is subject to clinical trial outcomes and regulatory approval [sec_mda · as of 2026-08-06].
What to watch
- Phase 3 topline results for CRB-701 expected on 2029-03-01 [catalyst].
- Enrollment progress and data from ongoing Phase 1/2 trial of CRB-701 [sec_mda · as of 2026-08-06].
- Cash burn rate and any new financing activities to extend runway beyond twelve months [sec_mda · as of 2026-08-06].
- Updates on CRB-913 Phase 1b clinical study and any subsequent development plans [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Corbus Pharmaceuticals Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Corbus Pharmaceuticals Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
11.6 months
D/E 0.24 · 0% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~914d
3 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
103
Total value held
$91.3M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 1,737,287 | $16.3M |
| vanguard capital management llc | 1,468,212 | $13.8M |
| citadel advisors llc | 806,560 | $7.6M |
| prosight management, lp | 697,108 | $6.5M |
| diadema partners lp | 555,257 | $5.2M |
| susquehanna international group, llp | 418,315 | $3.9M |
| adar1 capital management, llc | 366,781 | $3.4M |
| armistice capital, llc | 364,000 | $3.4M |
| renaissance technologies llc | 346,998 | $3.3M |
| blackrock, inc. | 271,636 | $2.6M |
Showing top 10 of 103 institutional holders of Corbus Pharmaceuticals Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 9.2%
- Days to cover
- 5.3
- Shares short
- 1,407,889
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRBP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Corbus Pharmaceuticals Holdings, Inc.?
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage oncology and obesity company developing a diversified portfolio of therapies, including CRB-701 and CRB-913, with no approved products and a history of operating losses.
What is Corbus Pharmaceuticals Holdings, Inc.'s lead drug candidate?
Corbus Pharmaceuticals Holdings, Inc.'s most advanced tracked candidate is CRB-601 (Phase 3) for Solid Tumor.
What is Corbus Pharmaceuticals Holdings, Inc.'s next catalyst?
Corbus Pharmaceuticals Holdings, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, 2-Arm Study to Evaluate the Efficacy and Safety of CRB-701 Compared With Investigator'" — expected March 1, 2029.
Who is the CEO of Corbus Pharmaceuticals Holdings, Inc.?
Dr. Yuval Cohen Ph.D. is the chief executive officer of Corbus Pharmaceuticals Holdings, Inc. (CRBP).
Where is Corbus Pharmaceuticals Holdings, Inc. headquartered?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is headquartered in Norwood, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.